Introduction
The number of percutaneous coronary intervention (PCI) as a therapeutic alternative to coronary artery bypass grafting (CABG) in patients with complex coronary stenosis is increasing. Current guidelines recommend PCI in such patients with high level of evidence. 1 Nevertheless, occurrence of complication during high-risk PCI may lead to the need for extra corporal circulation or emergency switch to CABG. To protect patients' circulation and especially coronary perfusion during or after PCI procedures, several devices have been evaluated. The use of intra-aortic balloon pump (IABP) is technically feasible for the interventional cardiologist, but current guidelines do not
Learning points
• Complications during percutaneous coronary intervention (PCI) can occur with sudden need for circulatory support.
• Circulatory support devices are a helpful tool during high-risk PCI to generate additional output or maintain sufficient circulation in critical situations.
• The iVAC2L is a transfemoral pulsatile ventricular assist device with up to 2l additional cardiac output during a high-risk PCI that may be useful to maintain an adequate circulation during haemodynamic critical situations. 2 Intra-aortic balloon pump use in cardiogenic shock failed to reduce 30 day mortality, 3 but several studies assumed a potential benefit in high-risk PCI. [4] [5] [6] The use of alternative full support circulatory assist devices guarantees an adequate circulation at the expense of a complex setting including technicians during PCI, which is often only available in tertiary care centre, and show higher rates of adverse advents compared to IABP. 7, 8 Extra-corporal life support (ECLS) devices are able to maintain a sufficient cardiac output (CO), but the effects for the heart are not only positive. They increase afterload and do not allow unloading of the left ventricle. The implantation of a TandemHeart device (Cardiac Assist, Pittsburgh, PA, USA) is compared to ECLS less complex, but it requires at least an interventional cardiologist that is familiar with the trans-septal puncture manoeuvre, and it has more bleeding and ischaemic complications compared to IABP because of the larger insertion cannulae. 9 An alternative is the Impella device which may reduce major adverse events after high-risk PCI compared to IABP. 10 Pulsatile devices like the iVAC3L system (PulseCath BV, Amsterdam, The Netherlands) enable LV unloading and generate an additional CO up to 3 L/minute, but again the insertion requires surgical support for preparation of the right subclavian artery access.
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The iVAC2L device (PulseCath BV, Amsterdam, The Netherlands) is able to generate an additional CO up to 2 L/minute. 12 Its safety and feasibility has been reported very recently. 13 It is inserted via a trans-femoral access with placement of the 17 Fr, 100 cm long single lumen catheter in the left ventricular outflow tract via the aortic valve. 12 During systole blood is aspirated from the left ventricle and in diastole it is directed back in the aortic arch. 12 The pulsatile function is steered by electrocardiogram (ECG) or aortic pressure; in contrast to the Impella 2.5 system (ABIOMED, Danvers, MA, USA) it generates a pulsatile flow, and it is driven and compatible with conventional IABP consoles, which are still available in many hospitals.
9,12
Timeline Case report
We report on the case of an 80-year-old male former smoker admitted to our hospital with typical angina. The patient described a first occurrence of symptoms after a pulmonary infection a couple of month ago associated with palpitations. Sick sinus syndrome was assumed due to symptoms of irregular tachycardia in combination with presyncope. Physical examination did not reveal any abnormalities of pulse, cardiac murmurs, or rale. Recurrent Holter ECG examinations did not detect any arrhythmias. The patient was treated with aspirin 100 mg/day, atenolol 25 mg/day, candesartan 8 mg/day, and hydrochlorothiazide 12.5 mg/day. Biomarkers of myocardial necrosis were not elevated; troponin T 9.6 pg/mL (cut off < _ 14 pg/mL) and Creatine Kinase 85 U/L (cut off < 170 U/L). Coronary angiography revealed a relevant ostial stenosis of left circumflex artery (LCX) and haemodynamic relevant stenosis of an almost intermediate proceeding obtuse marginal artery (OM) (Figure 1 ). During invasive diagnostics, a massive vasospasm of the right coronary artery (RCA) occurred which led to ventricular fibrillation. The patient was successfully defibrillated with 360 J. Coronary angiography was stopped and, despite of a normal left ventricular ejection fraction of 63%, highrisk PCI under circulatory support was planned for the next week. Treatment with atenolol was stopped. Relevant peripheral artery disease was excluded by computed tomography of the aortic bifurcation. After the patient gave written informed consent, we placed a 6 Fr radial access on the right side. We decided to use the IVAC2L device for haemodynamic support during PCI and placed two ProGlide closure devices in the right femoral artery and inserted a SoloPath re-collapsible 13. Figure 3) . The iVAC2L device worked well, no cardiopulmonary resuscitation (CPR) or inotropic agents were necessary. We were able to stabilize the patient with atropine i.v. and later nitrate bolus i.v. After 2 minutes vasospasm, ST elevations disappeared completely and the patient was again in stable haemodynamic condition. PCI with insertion of an ostial LCX drugeluting stent and insertion of one drug-eluting balloon into the OM was performed with excellent primary results ( Figure 4) . The whole procedure was performed in a spontaneous breathing patient with only local anaesthesia in the radial and femoral access areas. Measurements of mean blood pressure showed an increase of 10 mmHg under 1:1 mechanical support. After PCI, the device catheter was removed from the aorta. The right femoral access sheath was collapsed and removed and the access was closed with the two ProGlide devices. We observed the patient on our intensive care unit until the next day, no complications in the region of artery accesses occurred. The patient left our hospital 2 days after PCI in good clinical condition. Because of the assumed arrhythmia, 2 months later the patient underwent invasive electrophysiological examination in our hospital without any abnormal findings. At this point, the patient was free of any angina or cardiac symptoms.
Discussion
High-risk PCI is becoming an alternative to CABG. 1 The majority of surgical procedures are performed under extra-corporal circulation to guarantee sufficient blood flow. To enable sufficient CO and coronary blood flow, especially during complex PCI settings, several devices have been developed. 14 A few years ago the IABP was widely used and assumed to increase coronary perfusion and to generate an additional CO up to 0.5 L/minute. In randomized controlled trials, it failed to show lower mortality rates or circulatory benefit in cardiogenic shock settings 3 and no additional positive effects were shown in a prophylactic implantation setting compare to stand-by use. 4 As described above, the routinely use of IABP is not recommended anymore. 2 Left ventricular assist device or extra-corporal membrane oxygenation support during high-risk PCI is not well investigated and the implantation of the devices and the maintenance of the support are complex. 14 Recently, we have reported the first use of the iVAC2L by interventional cardiologists during high-risk PCI in Germany 15 and its safety and feasibility was shown in a singlecentre study. 13 Actually, we are able to report the first successful prevention of CPR during high-risk PCI. Thus, we cannot only assume a safe, feasible, and easy use of the iVACL device in combination with the 13 Fr sheet and the ProGlide device during PCI but also a positive haemodynamic benefit of the device. The iVAC2L device may be a useful and efficient alternative to the IABP system and an alternative to the Impella 2.5. Its pulsatile flow and the larger lumen may provide a more sufficient left ventricular unloading and a lower haemolysis. It is easy use in combination with a standard IABP console that should be still available in most catheter labs.
On the other hand, the access sheet is significantly larger. Its additional CO is not comparable to a conventional ECMO system or the TandemHeart, but the implantation of the device is less complex without the need for cardiac technicians or additional trans-septal puncture manoeuvre. 9 Thus, the circulatory support and patients' benefit of the iVAC2L device needs to be investigated in large multi-centre studies.
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